Search

Displaying results 1181 - 1190 of 3917 in total
  1. Drug

    Cinacalcet

    go.drugbank.com/drugs/DB01012
    ApprovedInvestigational

    Cinacalcet is a calcimimetic sold by Amgen under the trade name Sensipar® in North America and Australia and as Mimpara® in Europe. It is used to treat hyperparathyroidism due to parathyroid tumours or renal failure.

  2. Drug

    Carvedilol

    go.drugbank.com/drugs/DB01136
    ApprovedInvestigational

    [A182306] Carvedilol was granted FDA approval on 14 September 1995.[L7889]

  3. Drug

    Mitapivat

    go.drugbank.com/drugs/DB16236
    ApprovedInvestigational

    [A245478] On January 5, 2026, the FDA also approved the use of in the treatment of anemia in adults with alpha- or beta-thalassemia, making it the first oral treatment for this condition.[L54953] … [A245478] On February 17, 2022, the FDA approved mitapivat as the first disease-modifying treatment for hemolytic anemia in adults with pyruvate kinase (PK) deficiency, a rare, inherited disorder leading

  4. Drug

    Calaspargase pegol

    go.drugbank.com/drugs/DB14730
    ApprovedInvestigational

    Calaspargase pegol, by _Shire_ pharmaceuticals, was approved by the FDA on December 20, 2018 for acute lymphoblastic anemia (ALL) [L4890].

  5. Indication

    Atrial Fibrillation (AF)

    go.drugbank.com/conditions/DBCOND0047324
    Drugs: Acenocoumarol · Acetylsalicylic acid · Amiodarone · Atenolol · Azilsartan medoxomil · Bisoprolol +16 more
  6. Drug

    Tick-borne encephalitis vaccine (whole virus, inactivated)

    go.drugbank.com/drugs/DB16611
    ApprovedInvestigational

    [L36120] TICOVAC was granted FDA approval on August 13, 2021.[L36050] … [A237520] Both vaccines are based on formaldehyde-inactivated whole virus.

  7. Drug

    Sparsentan

    go.drugbank.com/drugs/DB12548
    ApprovedInvestigational

    [L45300] On April 24, 2024, sparsentan was granted conditional marketing authorization by the European Commission for the treatment of adults with primary IgAN.[L51559] … Furthermore, it is the first non-immunosuppressive therapy for the reduction of proteinuria in IgAN.[L45315] The use of sparsentan may cause hepatotoxicity and embryo-fetal toxicity.

    Categories: Agents Acting on the Renin-Angiotensin System
  8. Drug

    Phosmet

    go.drugbank.com/drugs/DB11448
    ExperimentalVet approved

    It is a non-specific insecticide. It is mainly used on apple trees to control codling moths. … It is also used on other fruit crops, ornamentals, and vines to control aphids, suckers, mites, and fruit flies.

  9. Drug

    Larotrectinib

    go.drugbank.com/drugs/DB14723
    ApprovedInvestigational

    On April 10, 2025, the FDA granted full drug approval.[L52805]

  10. Drug

    Tegafur

    go.drugbank.com/drugs/DB09256
    ApprovedInvestigational

    Tegafur (INN, BAN, USAN) is a prodrug of [DB00544] (5-FU), an antineoplastic agent used as the treatment of various cancers such as advanced gastric and colorectal cancers. … When converted and bioactivated to 5-FU, the drug mediates an anticancer activity by inhibiting thymidylate synthase (TS) during the pyrimidine pathway involved in DNA synthesis. 5-FU is listed on the